| Morschhauser, Franck |
ALLELE, NCT03394365 / 2017-002949-30: Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy |
|
|
| Recruiting | 3 | 66 | Europe, Canada, US, RoW | tabelecleucel, tab-cel®, ATA129, EBV-CTL | Atara Biotherapeutics | Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications | 08/25 | 06/27 | | |
|
RELEVANCE , NCT01650701 / 2011-002792-42: A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma |
|
|
| Completed | 3 | 1030 | Europe, Canada, RoW | Rituximab, mabthera, rituxan, Lenalidomide, Revlimid, Rituximab - CHOP, Rituximab - CVP, Rituximab - Bendamustine | The Lymphoma Academic Research Organisation, Celgene Corporation | Follicular Lymphoma | 05/17 | 04/24 | | |
|
|
| Completed | 3 | 255 | Japan, US | Rituximab, Lenalidomide, Revlimid, Rituximab-CHOP, Rituximab-CVP, Rituximab-Bendamustine | Celgene, The Lymphoma Academic Research Organisation | Follicular Lymphoma | 04/24 | 04/24 | | |
|
MorningLyte, NCT06284122: Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 |
|
|
| Recruiting | 3 | 790 | Europe | Mosunetuzumab, Lenalidomide, Rituximab, Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristin, Prednisone, Bendamustin | The Lymphoma Academic Research Organisation, Lymphoma Study Association, Swiss Group for Clinical Cancer Research, Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Follicular Lymphoma | 11/28 | 04/34 | | |
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. |
|
|
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab | Epizyme, Inc. | Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma | 03/26 | 03/29 | | |
|
|
|
|
|
|
|
| Active, not recruiting | 2 | 74 | Europe | Pixantrone, Pixuvri, Ifosfamide, Holoxan, Etoposide, Vepeside, Rituximab, Mabthera, Transplant | The Lymphoma Academic Research Organisation | Aggressive Non-Hodgkin Lymphoma | 06/19 | 03/25 | | |
NCT03766763: Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage a |
|
|
| Active, not recruiting | 2 | 82 | Europe | Venetoclax | French Innovative Leukemia Organisation | Chronic Lymphoid Leukemia | 01/22 | 04/30 | | |
ALYCANTE, NCT04531046: Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation |
|
|
| Active, not recruiting | 2 | 62 | Europe | axicabtagene ciloleucel, axi-cel | The Lymphoma Academic Research Organisation | B-Cell Lymphoma Refractory, B-cell Lymphoma Recurrent | 04/22 | 06/26 | | |
| Active, not recruiting | 2 | 67 | Europe | Obinutuzumab, gazyva, RO7082859, glofitamab | The Lymphoma Academic Research Organisation | Diffuse Large B-Cell Lymphoma Refractory, Refractory Indolent Adult Non-Hodgkin Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma, Refractory Primary Mediastinal Large B-Cell Cell Lymphoma, Refractory Mantle Cell Lymphoma | 01/23 | 03/26 | | |
| Active, not recruiting | 2 | 141 | Europe | Valemetostat tosylate, DS-3201b | The Lymphoma Academic Research Organisation, Daiichi Sankyo | Lymphoma, B-Cell | 10/24 | 10/24 | | |
NCT06271057: Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse |
|
|
| Recruiting | 2 | 65 | Europe | golcadomide, BMS-986369, CC-99282 | The Lymphoma Academic Research Organisation, Lymphoma Study Association | Diffuse Large B-cell Lymphoma Refractory, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma, Refractory High Grade B-Cell Lymphoma | 01/26 | 10/27 | | |
| Recruiting | 2 | 56 | Europe | Lacutamab, Gemcitabine, Oxaliplatine | The Lymphoma Academic Research Organisation, Innate Pharma | Peripheral T Cell Lymphoma, Relapse/Recurrence | 01/25 | 01/27 | | |
|
GLOASIS, NCT06558604: A Phase II Study Evaluating Glofitamab in Combination With Venetoclax Plus Zanubrutinib or Venetoclax Alone in Subjects With Untreated or Relapsed/Refractory High-risk Mantle-cell Lymphoma |
|
|
| Recruiting | 2 | 100 | Europe | Obinutuzumab, Glofitamab, Venetoclax Oral Product, Zanubrutinib Oral Capsule | The Lymphoma Academic Research Organisation, BeiGene, Hoffmann-La Roche | Lymphoma, Mantle-Cell | 05/28 | 03/32 | | |
| Recruiting | 2 | 180 | Europe, Japan, US, RoW | Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid® | Genmab, AbbVie | Diffuse Large B-Cell Lymphoma | 01/26 | 03/27 | | |
OASIS-II, NCT04802590: Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma |
|
|
| Recruiting | 2 | 194 | Europe | Ibrutinib 560 mg, Venetoclax 10 MG Oral Tablet [Venclexta], Venetoclax 50 MG Oral Tablet [Venclexta], Venetoclax 100 MG Oral Tablet [Venclexta] | The Lymphoma Academic Research Organisation, Institute of Cancer Research, United Kingdom | Mantle Cell Lymphoma | 03/26 | 09/31 | | |
NCT01582776 / 2011-005150-62: Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma |
|
|
| Completed | 1/2 | 317 | Europe | Lenalidomide and GA101, Revlimid, Obinutuzumab | The Lymphoma Academic Research Organisation | Follicular Lymphoma Patients (Phase IB), Follicular and Agressive (DLBCL&MCL) B-cell Lymphoma Patients (Phase II) | 07/18 | 05/22 | | |
| Recruiting | 1/2 | 118 | Europe, RoW | Lenalidomide, Revlimid, Ibrutinib, Imbruvica | Institut Curie, National Cancer Institute, France | Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Primary | 02/25 | 02/35 | | |
| Recruiting | 1/2 | 184 | Europe, US, RoW | IPH6501 | Innate Pharma | Non Hodgkin Lymphoma | 12/28 | 12/28 | | |
NCT02576496: Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies |
|
|
| Completed | 1 | 106 | Europe, US | Tinostamustine, EDO-S101 | Mundipharma Research Limited | Hematological Malignancies, Multiple Myeloma, Hodgkin's Lymphoma, Cutaneous T Cell Lymphoma | 05/23 | 11/23 | | |
ALK-OBS, NCT03603847: Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma |
|
|
| Completed | N/A | 41 | Europe | | The Lymphoma Academic Research Organisation, Hôpital Necker-Enfants Malades, Fondation ARC, Pfizer, Takeda | Anaplastic Large Cell Lymphoma, ALK-Positive | 06/23 | 06/23 | | |
NCT05529524: Signatures of Response and Resistance to Mosunetuzomab in Follicular Lymphomas (FL) |
|
|
| Completed | N/A | 6 | Europe | | The Lymphoma Academic Research Organisation, Roche Pharma AG | Follicular Lymphoma | 01/24 | 01/24 | | |
| Recruiting | N/A | 6000 | Europe | Real-life epidemiological platform of lymphoma in France | Hospices Civils de Lyon, The Lymphoma Academic Research Organisation | Diffuse Large B Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), T-cell Lymphoma (T-NHL), Hodgkin's Lymphoma (HL), Burkitt Lymphoma (BL)) | 11/27 | 11/27 | | |
| Recruiting | N/A | 204 | Europe | Chemotherapy + follow up, Chemotherapy + ASCT + follow up | Hospices Civils de Lyon | Peripheral T Cell Lymphoma | 04/28 | 04/28 | | |
| JARDIN, Fabrice |
MorningLyte, NCT06284122: Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 |
|
|
| Recruiting | 3 | 790 | Europe | Mosunetuzumab, Lenalidomide, Rituximab, Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristin, Prednisone, Bendamustin | The Lymphoma Academic Research Organisation, Lymphoma Study Association, Swiss Group for Clinical Cancer Research, Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Follicular Lymphoma | 11/28 | 04/34 | | |
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
|
|
| Active, not recruiting | 3 | 440 | Europe, Canada, Japan, US, RoW | Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin | ADC Therapeutics S.A., ADC Therapeutics SA | Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | 06/25 | 06/28 | | |
|
|
|
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. |
|
|
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab | Epizyme, Inc. | Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma | 03/26 | 03/29 | | |
|
|
|
|
|
|
|
AVAJAK, NCT05198960: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms |
|
|
| Recruiting | 3 | 1308 | Europe | Direct Oral Anticoagulants, Low-dose aspirin | University Hospital, Brest | Polycythemia Vera, Essential Thrombocythemia, Prefibrotic/Early Primary Myelofibrosis, JAK2 V617F, High-risk Patients | 07/27 | 07/27 | | |
MARSUN, NCT06006117: Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma |
|
|
| Recruiting | 3 | 260 | Europe | Mosunetuzumab + Lenalidomide, Arm 1, - Rituximab + Lenalidomide (28-days cycles, Arm 2, - Rituximab + Bendamustine (28-days cycles), Arm 3, - Rituximab + CHOP (21-days cycles), Arm 4 | The Lymphoma Academic Research Organisation | Marginal Zone Lymphoma | 09/27 | 09/32 | | |
NCT06271057: Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse |
|
|
| Recruiting | 2 | 65 | Europe | golcadomide, BMS-986369, CC-99282 | The Lymphoma Academic Research Organisation, Lymphoma Study Association | Diffuse Large B-cell Lymphoma Refractory, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma, Refractory High Grade B-Cell Lymphoma | 01/26 | 10/27 | | |
VERLen, NCT04974216: Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older |
|
|
| Active, not recruiting | 2 | 71 | Europe | Tafasitamab, MOR208, Lenalidomide, Rituximab | The Lymphoma Academic Research Organisation | DLBCL | 07/24 | 12/26 | | |
Relyage, NCT04113226: Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 2 | 114 | Europe | Rituximab, Lenalidomide 20 MG, Comprehensive Geriatric Assessment (CGA), Activities of daily living (ADL) scale | Centre Hospitalier Universitaire, Amiens, cimiez hospital Nice, Institut Bergonié, groupe hospitalier public sud de l'oise, Henri Mondor University Hospital, Centre Henri Becquerel, Hôpital Charles Foix, Saint-Louis Hospital, Paris, France | Chemotherapy, Diffuse Large B-Cell Lymphoma (DLBCL), Nos, Elderly | 12/24 | 12/24 | | |
GLOASIS, NCT06558604: A Phase II Study Evaluating Glofitamab in Combination With Venetoclax Plus Zanubrutinib or Venetoclax Alone in Subjects With Untreated or Relapsed/Refractory High-risk Mantle-cell Lymphoma |
|
|
| Recruiting | 2 | 100 | Europe | Obinutuzumab, Glofitamab, Venetoclax Oral Product, Zanubrutinib Oral Capsule | The Lymphoma Academic Research Organisation, BeiGene, Hoffmann-La Roche | Lymphoma, Mantle-Cell | 05/28 | 03/32 | | |
| Recruiting | 1/2 | 118 | Europe, RoW | Lenalidomide, Revlimid, Ibrutinib, Imbruvica | Institut Curie, National Cancer Institute, France | Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Primary | 02/25 | 02/35 | | |
| Terminated | N/A | 139 | Europe | blood sample analyses | Intergroupe Francophone du Myelome | Multiple Myeloma, Covid19 | 12/22 | 12/22 | | |
| Recruiting | N/A | 100 | Europe | Physical exercises, Optional physical exercises | Centre Hospitalier Universitaire, Amiens, University Hospital, Rouen, University Hospital, Caen | Physical Activity, Multiple Myeloma, Quality of Life | 05/23 | 12/23 | | |
| Not yet recruiting | N/A | 12 | Europe | Measure of the circulating tumor DNA | Centre Henri Becquerel | Diffuse Large B Cell Lymphoma | 11/24 | 05/25 | | |
DECLAM, NCT03450512: Incidence of Neutropenic Enterocolitis Study in Acute Myeloid Leukemia Patients During Intensive Therapy |
|
|
| Recruiting | N/A | 170 | Europe | prospective study on digestive affections in an homogeneous cohort of hematological patients | Centre Hospitalier Universitaire, Amiens | Acute Myeloid Leukemia | 11/24 | 11/24 | | |
| Recruiting | N/A | 100 | Europe | fundoscopic picture, blood sample, bone marrow sample | Centre Hospitalier Universitaire, Amiens, Centre Hospitalier Saint Vincent, Centre Henri Becquerel, University Hospital, Caen, University Hospital, Lille, Centre Hospitalier de Lens | Hyperviscosity Syndrome, Waldenstrom Macroglobulinemia | 05/24 | 08/24 | | |
SLP-rares, NCT04893564: Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström Macroglobulinemia |
|
|
| Withdrawn | N/A | 90 | Europe | bone marrow sample, blood sample | Centre Hospitalier Universitaire, Amiens, Centre Henri Becquerel, University Hospital, Caen, University Hospital, Lille, Centre Hospitalier de Lens | Waldenstrom's Disease, Waldenstrom Macroglobulinemia | 05/24 | 05/24 | | |
REMODALLO, NCT05161026: Impact of Allo-HSCT on Bone Remodeling: Evolution of Bone Mineral Density and Architecture Measured by Bone Densitometry |
|
|
| Not yet recruiting | N/A | 120 | Europe | Bone osteodensitometry | University Hospital, Caen | Myeloid Leukemia, Acute | 12/26 | 12/27 | | |
| Recruiting | N/A | 6000 | Europe | Real-life epidemiological platform of lymphoma in France | Hospices Civils de Lyon, The Lymphoma Academic Research Organisation | Diffuse Large B Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), T-cell Lymphoma (T-NHL), Hodgkin's Lymphoma (HL), Burkitt Lymphoma (BL)) | 11/27 | 11/27 | | |
NCT04220970: Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry |
|
|
| Recruiting | N/A | 150 | Europe | BIA-ALCL | The Lymphoma Academic Research Organisation | Anaplastic Large Cell Lymphoma Associated With Breast Implants (BIA-ALCL) | 06/32 | 06/32 | | |
| Recruiting | N/A | 5000 | Europe | | The Lymphoma Academic Research Organisation, Gilead Sciences, Novartis, Bristol-Myers Squibb | Hematopathology Eligible or CAR-t Cell Treatment | 12/38 | 12/38 | | |
| Ciuffreda, Libero |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
| Shi, Jian |
Circular, NCT05411705: Efficacy and Safety of rhTPO's Prophylactic Treatment of CTIT in Patients With High Risk of Cardiac Injury |
|
|
| Recruiting | 4 | 165 | RoW | rhTPO, Recombinant human thrombopoietin, TPIAO, Control, No intervention | The First Affiliated Hospital of Dalian Medical University, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Anqing Municipal Hospital, Henan Cancer Hospital, Wuhan Union Hospital, China, Peking University Shougang Hospital, Chinese PLA General Hospital, Liaoning Tumor Hospital & Institute, Tianjin Medical University Cancer Institute and Hospital, Henan Provincial People's Hospital, Shanxi Provincial Cancer Hospital, Beijing Sanhuan Cancer Hospital, Hebei Medical University Fourth Hospital, Tongji Hospital, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, Bethune Charitable Foundation | Cancer Treatment Induced Thrombocytopenia | 06/24 | 08/24 | | |
NCT04282278: Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid Tumor |
|
|
| Recruiting | 2 | 180 | RoW | Camrelizumab/sintilimab+ Standard chemotherapy, Camrelizumab/sintilimab+ apatinib（Intolerance to chemotherapy / refuse chemotherapy）, Camrelizumab/sintilimab+ apatinib+ Standard chemotherapy | Hebei Medical University Fourth Hospital | Advanced Solid Tumor | 04/22 | 04/24 | | |
NCT05688696: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus |
|
|
| Recruiting | 2 | 186 | RoW | Orelabrutinib (Low Dose), Orelabrutinib (High Dose), Orelabrutinib Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Systemic Lupus Erythematosus, SLE | 08/25 | 05/26 | | |
NCT06056115: Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain Metastatic |
|
|
| Recruiting | N/A | 20 | RoW | Tislelizumab,Platinum | Hebei Medical University Fourth Hospital | Lung Adenocarcinoma | 04/25 | 12/26 | | |
| LIU, LIHong |
NCT05236621: A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma |
|
|
| Active, not recruiting | 3 | 85 | RoW | Pomalidomide, Dexamethasone | Qilu Pharmaceutical Co., Ltd. | Multiple Myeloma, Recurrent or Refractory | 06/22 | 12/23 | | |
NCT06363994: A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL |
|
|
| Recruiting | 3 | 476 | RoW | Orelabrutinib, Bendamustine Injection, Rituximab, Orelabrutinib Placebo | InnoCare Pharma Inc. | Mantle Cell Lymphoma | 06/31 | 06/32 | | |
NCT04578613: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL |
|
|
| Recruiting | 3 | 218 | RoW | ICP-022, Chlorambucil, Rituximab | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 06/25 | | |
NCT05051891: A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 356 | RoW | Orelabrutinib and R-CHOP, R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Treatment-naїve Mantle Cell Lymphoma | 12/24 | 12/27 | | |
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. |
|
|
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab | Epizyme, Inc. | Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma | 03/26 | 03/29 | | |
|
|
|
|
|
|
|
ICP-CL-01203, NCT06378138: ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
|
|
| Recruiting | 2/3 | 226 | RoW | ICP-248, Orelabrutinib | Beijing InnoCare Pharma Tech Co., Ltd. | Hematologic Malignancies | 11/30 | 07/31 | | |
NCT04324879: A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL) |
|
|
| Recruiting | 2 | 80 | RoW | TQ-B3525 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Relapsed / Refractory Follicular Lymphoma | 12/22 | 12/22 | | |
| Completed | 2 | 3 | RoW | ICP-022 | Beijing InnoCare Pharma Tech Co., Ltd. | Diffuse Large B Cell Lymphoma | 11/21 | 12/21 | | |
NCT05716087: A Study of Rocbrutinib in Participants with Relapse or Refractory Mantle Cell Lymphoma |
|
|
| Active, not recruiting | 2 | 62 | RoW | Rocbrutinib, NWP-775, LP-168 | Guangzhou Lupeng Pharmaceutical Company LTD. | Mantle Cell Lymphoma (MCL) | 12/24 | 12/25 | | |
| Not yet recruiting | 2 | 30 | RoW | R-EPOCH in Combination With Ibrutinib | Institute of Hematology & Blood Diseases Hospital, Xian-Janssen Pharmaceutical Ltd. | Richter Transformation | 08/24 | 08/25 | | |
NCT04494503: Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL |
|
|
| Recruiting | 1/2 | 123 | RoW | APG-2575, Rituximab, Ibrutinib | Ascentage Pharma Group Inc. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 12/25 | | |
NCT05104775: A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy |
|
|
| Recruiting | 1 | 58 | RoW | GNC-035 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc. | Hematologic Malignancies | 06/25 | 12/25 | | |
NCT04497688: Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's Lymphoma |
|
|
| Recruiting | N/A | 104 | RoW | PEG-rhG-CSF | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd., Hebei Medical University Fourth Hospital | Non Hodgkin's Lymphoma | 09/20 | 10/20 | | |
NCT04678089: Evaluation of Clinical Treatment of Multiple Myeloma Based on Multi-omics |
|
|
| Enrolling by invitation | N/A | 350 | RoW | Bortezomib, PS-341, VELCADE | Beijing Chao Yang Hospital | Multiple Myeloma, Bortezomib | 12/22 | 12/23 | | |
NCT04665063: A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma |
|
|
| Recruiting | N/A | 20 | RoW | Auto CAR-T, Cyclophosphamide,Fludarabine, Leukapheresis | Hebei Senlang Biotechnology Inc., Ltd., Hebei Medical University Fourth Hospital | Hodgkin's Lymphoma | 10/23 | 10/25 | | |
NCT04665076: Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors |
|
|
| Recruiting | N/A | 60 | RoW | Auto CAR-T, Cyclophosphamide,Fludarabine, Leukapheresis | Hebei Senlang Biotechnology Inc., Ltd., Hebei Medical University Fourth Hospital | Plasma Cell Tumors | 10/23 | 10/25 | | |
NCT04666168: A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's Lymphoma |
|
|
| Recruiting | N/A | 200 | RoW | Auto CAR-T, Cyclophosphamide,Fludarabine, Leukapheresis | Hebei Senlang Biotechnology Inc., Ltd., Hebei Medical University Fourth Hospital | Non-hodgkin's Lymphoma | 10/23 | 10/25 | | |
RCG, NCT04660630: A Real World Research: Comparison of Precision and Experience Therapy for Hypertension, Diabetes or Hyperlipidemias |
|
|
| Active, not recruiting | N/A | 1172 | RoW | Gene detection of therapeutic drugs for chronic cardiovascular and cerebrovascular diseases, Drug gene chip, Regular follow-up and patient education | Beijing Chao Yang Hospital, China development research foundation | Hypertension,Essential, Diabetes type2, Hyperlipidemias | 12/23 | 01/25 | | |
NCT04837222: A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma |
|
|
| Active, not recruiting | N/A | 1000 | RoW | No Intervention | Takeda | Lymphoma | 06/26 | 06/26 | | |
| Wang, Jun |
NCT04728516: The Effect of Dual Eradication Therapy vs PPI on Gastrointestinal Bleeding in ACS Patients |
|
|
| Not yet recruiting | 4 | 2600 | RoW | Vonoprazan-based dual eradication therapy for two weeks, amoxicillin, Pantoprazole | Qilu Hospital of Shandong University | Acute Coronary Syndrome, Helicobacter Pylori Infection | 01/23 | 06/23 | | |
| Recruiting | 4 | 40 | RoW | Thymosin Alpha1, thymalfasin, Immunosuppressant, Prednisone, Cortisone, Mycophenolate Mofetil, Tacrolimus | Jun Wang | IrAE | 11/24 | 04/25 | | |
NCT05604859: Evaluate the Efficacy and Safety of Various Treatment Schemes for Severe Fever With Thrombocytopenia Syndrome(SFTS) |
|
|
| Recruiting | 4 | 350 | RoW | Methylprednisolone, intravenous immunoglobulin, Tocilizumab, Low molecular weight heparin, conventional treatment | Qin Ning | Severe Fever With Thrombocytopenia Syndrome | 12/23 | 06/24 | | |
NCT06009042: Efficacy of Intravenous Immunoglobulin in Patients With Hemorrhagic Fever With Renal Syndrome: a Prospective Study |
|
|
| Recruiting | 4 | 100 | RoW | IVIG 20g/d, IVIG 10g/d | Tongji Hospital | HFRS (Hemorrhagic Fever With Renal Syndrome) | 06/24 | 06/24 | | |
NCT04726501: CCCG-HD-2018 for Children and Adolescents With Newly Diagnosed Hodgkin Lymphoma |
|
|
| Recruiting | 4 | 200 | RoW | Combined chemotherapy with or without involved-field radiotherapy | Children's Cancer Group, China, Shanghai Children's Medical Center | Hodgkin Lymphoma | 12/25 | 12/27 | | |
NCT05830500: Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma |
|
|
| Recruiting | 4 | 360 | RoW | Anlotinib Hydrochloride Capsule | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Medullary Thyroid Cancer | 06/27 | 12/28 | | |
| Recruiting | 3 | 315 | RoW | TQB2450, Anlotinib, TQB2450(blank), Anlotinib(blank) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Stage III Non-small-cell Lung Cancer | 12/22 | 03/25 | | |
| Active, not recruiting | 3 | 291 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib | Loxo Oncology, Inc., Eli Lilly and Company | Medullary Thyroid Cancer | 05/23 | 02/26 | | |
NCT05042375: A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 450 | RoW | camrelizumab + famitinib, pembrolizumab, camrelizumab | Jiangsu HengRui Medicine Co., Ltd. | Non-small Cell Lung Cancer | 12/23 | 12/25 | | |
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 3 | 864 | Europe, Canada, Japan, US, RoW | Dostarlimab, Placebo | GlaxoSmithKline | Neoplasms, Head and Neck | 05/28 | 07/29 | | |
NCT06333821: A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma |
|
|
| Not yet recruiting | 3 | 460 | NA | Nimotuzumab, Cisplatin, External Beam Radiotherapy (EBRT), Brachytherapy, placebo for Nimotuzumab, placebo | Biotech Pharmaceutical Co., Ltd. | Cervical Cancer | 04/30 | 04/30 | | |
NCT06616532: PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 404 | RoW | PM8002, Paclitaxel, Topotecan | Biotheus Inc. | SCLC | 01/27 | 12/28 | | |
NCT04102982: Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer |
|
|
| Recruiting | 2 | 200 | RoW | Camrelizumab, Camrelizumab plus microwave ablation, Camrelizumab plus MWA | Shandong Provincial Hospital | NSCLC Stage IV | 10/21 | 02/22 | | |
NCT03977480: Phase II Study of Hemay007 in Patients With Active Ulcerative Colitis |
|
|
| Terminated | 2 | 70 | RoW | Hemay007, Placebo | Tianjin Hemay Pharmaceutical Co., Ltd | Ulcerative Colitis | 08/22 | 08/22 | | |
NCT05254665: A Study of Docetaxel Polymeric Micelles for Injection in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 2 | 110 | RoW | Docetaxel Polymeric Micelles for Injection | Jiangsu Simcere Pharmaceutical Co., Ltd. | Advanced Solid Tumors | 12/22 | 03/24 | | |
NCT04286958: A Study of Camrelizumab As Consolidation Therapy After Radical Concurrent Chemoradiotherapy In Locally Advanced ESCC |
|
|
| Recruiting | 2 | 40 | RoW | Camrelizumab | Hebei Medical University Fourth Hospital | Esophageal Cancer | 12/22 | 03/23 | | |
| Recruiting | 1/2 | 280 | RoW | SAF-189s, foritinib succinate | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Advanced Cancer, Advanced Solid Tumor, Lung Cancer, Nonsmall Cell | 12/22 | 03/26 | | |
TQB2618-AK105-Ib-02, NCT05783921: A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 1/2 | 60 | RoW | TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin, Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Squamous Cell Carcinoma | 08/24 | 01/25 | | |
| Recruiting | N/A | 120 | RoW | Acupuncture, Rehabilitation, Rehabilitation treatment | Shanghai University of Traditional Chinese Medicine, Fudan University | Ischemic Stroke, Paralysis | 12/21 | 12/21 | | |
| Recruiting | N/A | 630 | Europe, US, RoW | ROX index algorithm | Hospital Universitari Vall d'Hebron Research Institute | Acute Hypoxemic Respiratory Failure | 12/24 | 06/25 | | |
NCT03921281: Evaluating the Therapeutic Effect of Scalp Acupuncture Treatment for Motor Dysfunction in Children With Cerebral Palsy |
|
|
| Completed | N/A | 100 | RoW | scalp acupuncture treatment, Rehabilitation Treatment | Children's Hospital of Fudan University | Cerebral Palsy, Motor Dysfunction, Acupuncture | 12/22 | 12/22 | | |
NCT04853238: Chronic Obstructive Pulmonary Disease (COPD) Maintenance Treatment Patterns in China |
|
|
| Completed | N/A | 1507 | RoW | Prospective observational cohort study | GlaxoSmithKline | Pulmonary Disease, Chronic Obstructive | 11/22 | 02/23 | | |
NCT05379491: Application of Linaclotide Capsule in Bowel Preparation for Patients at High Risk of Inadequate Bowel Preparation |
|
|
| Completed | N/A | 720 | RoW | 3 L PEG + linaclotide, 3 L PEG + placebo | Zhiguo Liu | Colonoscopy | 06/23 | 07/23 | | |
NCT05654857: The Prevalence of Family-unit Helicobacter Pylori Infection in Jiangsu |
|
|
| Recruiting | N/A | 4000 | RoW | PCR test in the stool | Nanjing First Hospital, Nanjing Medical University | Helicobacter Pylori Infection | 08/23 | 08/23 | | |
PROFOUND, NCT06217900: a PROspective Case Control Study to Develop and Validate a Blood Test FOr mUlti-caNcers Early Detection（） |
|
|
| Recruiting | N/A | 16666 | RoW | | Shanghai Weihe Medical Laboratory Co., Ltd., Peking University People's Hospital | Cancer | 10/26 | 03/27 | | |
| Recruiting | N/A | 500 | RoW | | Tongji Hospital | HFRS | 12/23 | 12/23 | | |
NCT05513040: Clinical Course of Functional Dyspepsia and Factors Predicting Outcome in Patients Receiving Medication-based Treatment |
|
|
| Recruiting | N/A | 300 | RoW | | Air Force Military Medical University, China | Functional Dyspepsia | 03/25 | 06/25 | | |
NCT05503940: Association of Multiple Medications With the Severity of Dyspepsia |
|
|
| Recruiting | N/A | 600 | RoW | | Air Force Military Medical University, China | Dyspepsia | 12/23 | 06/24 | | |
NCT05723731: Effect of Transcutaneous Auricular Vagal Nerve Stimulation on Chronic Constipation |
|
|
| Terminated | N/A | 106 | RoW | taVNS, Laxative Agent | Air Force Military Medical University, China | Chronic Constipation | 07/23 | 09/23 | | |
NCT06330727: Effects of Coffee Consumption on Metabolic Markers in Adults With Prediabetes and Obesity |
|
|
| Recruiting | N/A | 100 | RoW | Coffee capsule, 0 sugar 0 fat black coffee, instant black coffee. Product standard code: Q/QC 0001S. Food production license number: SC10644190004159., Corn starch capsule, Edible corn starch. Product standard code: GB 31637. Food production license number: SC10313102300041. | Nanjing First Hospital, Nanjing Medical University | Prediabetes | 10/24 | 10/24 | | |
NCT05947461: Prevention of Post-ERCP Pancreatitis by Indomethacin Vs Diclofenac |
|
|
| Terminated | N/A | 1204 | RoW | 100mg diclofenac, 100mg indomethacin | Air Force Military Medical University, China | Post-ERCP Acute Pancreatitis, NSAIDs, Indomethacin, Diclofenac, Endoscopic Retrograde Cholangiopancreatography | 06/24 | 06/24 | | |
TACS, NCT06375408: Transcranial Alternating Current Stimulation Prevents Delirium in Patients With Subarachnoid Hemorrhage |
|
|
| Recruiting | N/A | 74 | RoW | Real transcranial alternating electrical stimulation, Sham transcranial alternating electrical stimulation | Xuanwu Hospital, Beijing | Subarachnoid Hemorrhage | 02/26 | 03/26 | | |
NCT06323265: A Real-world Study of Adebrelimab Combined With Chemotherapy±Chest Radiotherapy in Patients With Extensive Stage Small Cell Lung Cancer |
|
|
| Recruiting | N/A | 50 | RoW | Adebrelimab + chemotherapy, ±chest radiotherapy | Hebei Medical University Fourth Hospital | Extensive Stage Small Cell Lung Cancer | 04/25 | 04/26 | | |
